Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
February 14 2023 - 8:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the
Company”), a biotechnology company focused on discovering and
developing transformative therapeutics for patients, today
announces it has named Robert Martell, M.D., Ph.D. to its Board of
Directors.
Having been in the pharmaceutical industry for more than 20
years, Dr. Martell currently serves as Head of Research and
Development, as well as previously serving on the Board of
Directors for more than six years at Curis, Inc. He is also an
attending physician at Tufts Medical Center in Boston. Previously,
he has held management positions in numerous publicly traded and
private companies, including Epi-Cure Pharmaceuticals, Tesaro,
Inc., and Methylgene, Inc., as well as filling key roles at Big
Pharma, including Bayer and Bristol-Meyers Squibb.
In addition, he served in multiple other top-tier academic
hospitals, including Duke University, where he completed his
internal medicine residency and oncology fellowship, as well as
serving as an Assistant Professor and a Fellow in the Center for
the Study of Aging and Human Development. He also served as adjunct
Assistant Clinical Professor at Yale. Dr. Martell is widely
published with an impressive array of articles in peer-reviewed
medical journals. He received his medical training at Wayne State
University School of Medicine, a Ph.D. in pharmacology from the
University of Michigan and his Bachelor of Arts degree in chemistry
from Kalamazoo College.
“Robert’s extensive industry experience and deep understanding
of the issues associated with drug development, combined with his
ongoing practice makes him an ideal board member for Indaptus. I
look forward to collaborating with him to help guide the Company
toward continued success,” stated Roger Pomerantz, M.D., chairman
of Indaptus Therapeutics’ Board of Directors.
“As a practicing physician with deep oncology experience, and a
long-time veteran of the pharmaceutical industry, we believe Robert
is an ideal addition to our Board of Directors,” commented Jeffrey
Meckler, Indaptus Therapeutics’ Chief Executive Officer. “As a
clinical-stage company, we look forward to his input in our
development programs and his perspective as we continue to explore
our Decoy platform toward what we believe will be a novel approach
to treating cancer.”
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of
immunotherapy advances. The Company’s novel approach is based on
the hypothesis that efficient activation of both innate and
adaptive immune cells and pathways and the associated anti-tumor
and anti-viral immune responses will require a multi-targeted
package of immune system activating signals that can be
administered safely intravenously. Indaptus’ patented technology is
composed of single strains of attenuated and killed,
non-pathogenic, Gram-negative bacteria to produce a multiple TLR
agonist Decoy platform, with expected reduced systemic toxicity,
and ability to prime or activate many of the cells and pathways of
innate and adaptive immunity. Decoy20 represents an
antigen-agnostic technology that has produced in pre-clinical
studies single agent activity against metastatic pancreatic and
orthotopic colorectal carcinomas, single agent eradication of
established, antigen-expressing breast carcinoma, as well as
combination-mediated eradication of established hepatocellular
carcinomas and non-Hodgkin’s lymphomas with standard pre-clinical
models, including syngeneic mouse tumors and human tumor
xenografts. In those pre-clinical studies tumor eradication has
been observed with Decoy products in combination with anti-PD-1
checkpoint therapy, low-dose chemotherapy, non-steroidal
anti-inflammatory drug or an approved targeted antibody.
Combination-based tumor eradication produces innate and adaptive
immunological memory, involves activation of both innate and
adaptive immune cells and is associated with induction of innate
and adaptive immune pathways in tumors after only one i.v. dose of
Decoy product, with associated “cold” to “hot” tumor inflammation
signature transition. IND-enabling toxicology studies have
demonstrated safe i.v. administration, with no sustained induction
of hallmarks of cytokine release syndromes, possibly due to passive
targeting to liver, spleen and tumor, followed by rapid elimination
of the product. Indaptus products have also produced significant
single agent activity against chronic hepatitis B virus (HBV) and
chronic human immunodeficiency virus (HIV) infections in
pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements with the
meaning of the Private Securities Litigation Reform Act. These
include statements regarding management’s expectations, beliefs and
intentions regarding, among other things, our product development
efforts, business, financial condition, results of operations,
strategies, plans and prospects. Forward-looking statements can be
identified by the use of forward-looking words such as “believe”,
“expect”, “intend”, “plan”, “may”, “should”, “could”, “might”,
“seek”, “target”, “will”, “project”, “forecast”, “continue” or
“anticipate” or their negatives or variations of these words or
other comparable words or by the fact that these statements do not
relate strictly to historical matters. Forward-looking statements
relate to anticipated or expected events, activities, trends or
results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: our plans to develop and potentially commercialize its
technology, the timing and cost of our planned investigational new
drug application and any clinical trials, the completion and
receiving favorable results in any clinical trials, Indaptus’
ability to obtain and maintain regulatory approval of any product
candidate, our ability to protect and maintain its intellectual
property and licensing arrangements, our ability to develop,
manufacture and commercialize its product candidates, the risk of
product liability claims, the availability of reimbursement, the
influence of extensive and costly government regulation, and our
estimates regarding future revenue, expenses capital requirements
and the need for additional financing. More detailed information
about the risks and uncertainties affecting us is contained under
the heading “Risk Factors” included in our most recent Annual
Report on Form 10-K filed with the SEC on March 21, 2022, and in
other filings that we have made and may make with the Securities
and Exchange Commission in the future. All forward-looking
statements speak only as of the date of this press release and are
expressly qualified in their entirety by the cautionary statements
included in this press release. We undertake no obligation to
update or revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IRScott Birkby (investors)sbirkby@coreir.com
CORE IRJules Abraham (media)917-885-7378julesa@coreir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024